Evidence map›Paper›PMID 37103613›Full record

ArticleAnnals of hematology2023

T-cell lymphoma associated with dupilumab.

Mitsuhiro Shimada, Shojiro Inano, Toshiyuki Kitano

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Pooled it
  2. Article
  3. Tumors in the setting of dupilumab use: A review of the literature.The World Allergy Organization journal · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Mitsuhiro ShimadaHematology, Medical Research Institute Kitano Hospital, PIIF Tazuke-kofukai, 2-4-20 Ohgimachi, Kita-ku, Osaka, 530-8480, Japan. mshimada519@gmail.com.ORCID 0000-0002-4831-2391
Shojiro InanoHematology, Medical Research Institute Kitano Hospital, PIIF Tazuke-kofukai, 2-4-20 Ohgimachi, Kita-ku, Osaka, 530-8480, Japan.
Toshiyuki KitanoHematology, Medical Research Institute Kitano Hospital, PIIF Tazuke-kofukai, 2-4-20 Ohgimachi, Kita-ku, Osaka, 530-8480, Japan.
Kitano Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedLymphoma, T-CellAntibodies, MonoclonalHumansAntibodies, MonoclonalAntibodies, Monoclonal, Humanizeddupilumab

Identifiers

PMID37103613
OpenAlexW4367174432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.